Enliven Therapeutics opened lower at $50.69, compared with its previous close of $51.19. In the last trading session, the stock traded between $48.02 and $50.76. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 4 years ago in Enliven Therapeutics is now worth
$ 203.63
Giving a profit of
$ 103.63 (103.63%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 10 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-2.83 (-5.53%)
Day High
$50.76
Day Low
$48.02
Day Open
$50.69
Prev Close
$51.19
Volume
5,29,549
1W Return
2.34%
1M Return
18.43%
3M Return
-17.70%
6M Return
22.15%
1Y Return
146.24%
Fundamentals
Market Cap ($ Mn)
3,559
PE Ratio
-
PB Ratio
4.73
PEG Ratio
-
ROE
-25.64%
ROCE
-29.59%
EPS (TTM)
$-0.38
Investment Returns
1 Week
2.34%
1 Month
18.43%
3 Months
-17.70%
6 Months
22.15%
9 Months
72.66%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Jun 26
0.0
Sep 26
Updates
6Nov
Guggenheim reiterates Buy on Enliven Therapeutics, keeps $78 target
Guggenheim analyst Michael Schmidt reiterated a Buy rating on Enliven Therapeutics. The $78 price target was maintained by the analyst. The rating action reflects continued confidence in the company.
6 days ago
19Oct
HC Wainwright raises Enliven Therapeutics price target to $73
HC Wainwright maintains Buy rating on Enliven Therapeutics. Price target raised to $73 from $65. Analyst Robert Burns issued the revised recommendation.
24 days ago
1Sep
Enliven Therapeutics to present ELVN-001 Phase 1 data at SOHO 2026
Enliven Therapeutics to present ELVN-001 Phase 1 data at SOHO 2026. Presentations include an oral session and poster on September 9-10, 2026. Data is an encore from the European Hematology Association 2026 Congress. ELVN-001 targets CML patients with and without T315I mutations.
2mo ago
18Aug
William Blair initiates Enliven with Outperform on CML drug potential
William Blair initiates Enliven Therapeutics with an Outperform rating, driven by the potential of lead drug ELVN-001 to capture share in the $8.8 billion CML market. Positive Phase 1 data shows superior response rates compared to competitors, while $895.2 million in cash ensures funding through 2030.
2mo ago
6Aug
Enliven Therapeutics Q2 Results: EPS misses estimates by 22.5%
Enliven Therapeutics missed Q2 EPS estimates by 22.5%, reporting a loss of $(0.49) per share against an expected $(0.40). The loss per share was unchanged from the prior year, indicating no improvement in profitability despite stable operational losses.
3mo ago
9Jul
HC Wainwright raises Enliven Therapeutics price target to $64
HC Wainwright & Co. analyst Robert Burns maintained a Buy rating on Enliven Therapeutics and raised the price target to $64 from $56, signaling a positive outlook for the NASDAQ-listed company.
